Biopharma-Reporter takes you inside the recently opened Testa BioProcess Innovation Center in Uppsala, Sweden, and speaks with CEO of GE Nordics, Lotta Ljungqvist.
NIBRT is embracing continuous bioprocessing says training director John Milne, who told us the method helps improve plant flexibility and could reduce manufacturing costs.
GE Healthcare opened its European Innovative Design and Advanced Manufacturing Technology Center last month. Biopharma-Reporter took a visit to Uppsala, Sweden to find out more.
Campaigning group People for the Ethical Treatment of Animals (PETA) picketed a conference in Boston on Tuesday to protest the use of animals in drug research and development.
Pall Corporation, GE Healthcare and LEWA Process Technologies showed off their latest downstream offerings to Biopharma-Reporter in Amsterdam last week.
Hands-on teaching offers drugmakers, vendors and regulators a better understanding of bioprocessing, according to the managing director of a training facility in Leiden, The Netherlands.
With Pfizer closing in on Hospira and Sandoz set to launch Zarxio in the US, it’s been a defining week for biosimilars, our BioFinance Vision feature explains.
The holidays are fast upon us, so let’s put ‘business’ to one side and get into the festive mood. To keep in the spirit of things, we’ve got a ‘gift’ for you – enjoy. Happy Holidays!
Aenova says the acquisition of Haupt Pharma and Patheon’s merger with DSM are evidence of consolidation in the CMO industry, as it looks to further increase its global footprint.
Catalent has increased its stake in Redwood Biosciences telling us it is committed to the development of antibody-drug conjugates (ADCs) and the SMARTag technology platform.
Patheon and DSM’s Pharma Products merger is “highly complementary” with crossover limited to North American oral solid manufacturing growth, says DPx as it targets further growth opportunities.
‘Podular’ manufacturing systems will dominate facility design within five years, say G-CON and GEA who have teamed with Pfizer to create a flexible, repurposable and portable facility.
When Frank Sinatra sang "If you can make it there, you can make it anywhere" in New York, New York he probably wasn't talking about biopharmaceutical production.
Over the last decade single-use technologies have moved into manufacturing scales and are increasingly being deployed worldwide, according to Thermo Fisher Scientific.
Purification bottlenecks, integrating single-use technologies and low cost companies are just some of the issues affecting the biotech industry today, according to experts at this year’s Interphex.
EMD Millipore premiered a new single-use bioreactor at Interphex 2012, claiming the new design addresses industry demand for ease of use and flexibility.
How have single-use technologies changed drug production? How do you dispose of a disposable technology? What will drive the market going forward? EMD Millipore answered these questions and more at Interphex 2011.
Recognition of glass vial quality issues is supporting interest in West’s analytical capabilities and Crystal Zenith (CZ) products, new sizes of which are being developed, said a company VP.
Flexibility is going to be a key driver for the pharmaceutical market in the next few years, according to Millipore's VP of downstream processing Paul Chapman.
